Company news

Immunic, Inc. news in 2026

Immunic, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Immunic to Participate in Investor Conferences in November

November 2, 2026

Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026

October 29, 2026

Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

October 21, 2026

Immunic Appoints Jaa Roberson as Chief People Officer

October 19, 2026

Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 13, 2026

Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

October 7, 2026

Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 29, 2026

Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026

September 2, 2026

Immunic Appoints Chitrang Davé as Chief Data and Digital Officer

September 1, 2026

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026

Immunic Appoints Elena Ridloff to Board of Directors

August 10, 2026

Immunic to Participate in Investor Conferences in July

July 9, 2026

Immunic to Participate in Investor, Industry and Scientific Conferences in June

June 10, 2026

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

May 28, 2026

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

May 27, 2026

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

May 18, 2026

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026

Immunic to Participate in Investor and Medical Conferences in May

April 30, 2026

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer

April 27, 2026

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

April 23, 2026

Immunic to Participate in Scientific and Medical Conferences in April

April 9, 2026

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

March 31, 2026

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

March 30, 2026

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

March 9, 2026

Immunic to Participate in Investor Conferences in March

March 3, 2026

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

February 26, 2026

Immunic Announces Closing of Oversubscribed Private Placement Financing

February 17, 2026

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

February 13, 2026

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

February 4, 2026

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

January 7, 2026

Decks in 2026